Cartesian Therapeutics, Inc. (RNAC)
(Real Time Quote from BATS)
$16.62 USD
+0.46 (2.85%)
Updated Jul 22, 2024 03:26 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Cartesian Therapeutics, Inc. [RNAC]
Reports for Purchase
Showing records 1 - 8 ( 8 total )
Company: Cartesian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Descartes-08 Can Shine Where Rivals Stumble; MG Data Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Cartesian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
RMAT Designation Earned for Descartes-08 in Myasthenia Gravis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Cartesian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Key Phase 2b Data Release Imminent; 1Q24 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Cartesian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Data Mid-2024 a Crucial Inflection Point; Reverse Split; Adjusting PT to $54
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Cartesian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Astellas Terminates Xork Collaboration; No Impact to Value; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Cartesian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Descartes-08 Phase 2b Data in Mid-2024; 2023 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Cartesian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New Manufacturing Facility Should Drive Production Scale; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Cartesian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A New Formula for CAR-T in Autoimmunity; Assuming at Buy and $2 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
|